EACR: A Matter of Life or Death: From Basic Cell Death Mechanisms to Novel Cancer Treatments

Read more about EACR: A Matter of Life or Death: From Basic Cell Death Mechanisms to Novel Cancer Treatments

February 1, 2018 4:00 AM (EST) - February 3, 2018 12:00 PM (EST)

Amsterdam, Netherlands

With its translational character, the conference has been designed for basic and translational cancer scientists, as well as oncologists who are interested in the multifaceted role of cell death in cancer.

Website

@EACRnews

Conference/Meeting

6th ACCELERATE Paediatric Oncology Conference 2018

Read more about 6th ACCELERATE Paediatric Oncology Conference 2018

February 8, 2018 4:00 AM (EST) - February 9, 2018 12:00 PM (EST)

Brussels, Belgium

The conference is part of a unique multi-stakeholder joint initiative; the ACCELERATE Platform. Co-organised by CDDF, ITCC and SIOPE, this platform provides a transparent forum enabling patients and parents organisations, academic paediatric oncologists and haematologists, pharmaceutical companies and EU regulatory network representatives to collaborate and jointly address specific obstacles to faster and more effective treatments for children and adolescents with cancer, including the needed changes to the Paediatric Medicines Regulation.

http://www.accelerate-platform.eu/annual-conferences-2/6th-accelerate-p…

@ITCC_eu

Conference/Meeting

ESMO Summit Africa 2018 – Oncology Updates: From Evidence to Practice

Read more about ESMO Summit Africa 2018 – Oncology Updates: From Evidence to Practice

February 14, 2018 3:00 AM (EST) - February 16, 2018 12:00 PM (EST)

Cape Town, South Africa

http://esmo.org/Conferences/ESMO-Summit-Africa-2018

The ESMO Summit Africa 2018 is a three-day educational event with presentations focused on several key disease sites. Created for oncology professionals in Africa by international and local key opinion leaders, the summit put into context the most significant treatment advances.

@ESMO

Conference/Meeting

ESMO Sarcoma and GIST Symposium

Read more about ESMO Sarcoma and GIST Symposium

February 5, 2018 4:00 AM (EST) - February 7, 2018 12:00 PM (EST)

Milan, Italy

Website

@ESMO

Conference/Meeting

Immuno-Oncology 360

Read more about Immuno-Oncology 360

February 7, 2018 4:00 AM (EST) - February 9, 2018 6:00 AM (EST)

New York, USA

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO (website)

@ConferenceForum

Conference/Meeting

Sohn Conference: Accelerating Translation of Pediatric Cancer Research

Read more about Sohn Conference: Accelerating Translation of Pediatric Cancer Research

February 26, 2018 3:00 AM (EST) - February 28, 2018 5:00 AM (EST)

London, UK

Organized by the New York Academy of Sciences

International conference (website)

@NYASciences

Conference/Meeting

DKFZ CONFERENCE 2018 on Preventive Oncology

Read more about DKFZ CONFERENCE 2018 on Preventive Oncology

February 15, 2018 4:00 AM (EST) - February 16, 2018 12:00 PM (EST)

Heidelberg, Germany

Conference website

The DKFZ CONFERENCE 2018 on Preventive Oncology will bring together internationally leading researchers who will present their recent work and expert views in the field of cancer prevention. As well as providing a broad overview of the diverse ongoing research activities in this area, the conference will provide an excellent networking platform for researchers to identify common interests and foster cooperative projects in cancer prevention.

@DKFZ

Conference/Meeting

Cancer Prevention Month (US)

Read more about Cancer Prevention Month (US)

February 1, 2018 10:00 AM (EST) - February 1, 2018 12:00 PM (EST)

USA

AICR’s “Cancer Prevention: Together We Can” campaign is a multi-layered effort
throughout the month of February.
AICR will:
• Issue a Public Service Announcement
• Offer a free downloadable 30-day CanPrevent Checklist for lowering risk
• Publish a host of interactive, evidence-based content on the CAN PREVENT website, prevent50.org
• Ask Americans to share on social media the healthy changes they are making

@aicrtweets

#cancerprevention

Twitter Promotional Event

Brain Tumour Conference

Read more about Brain Tumour Conference

May 1, 2018 10:00 AM (EDT) - May 3, 2018 12:00 PM (EDT)

London, UK

Cancer Research UK Brain Tumour Conference

Conference/Meeting

FAQ

How long does it take to become a Partner?

Typically it takes around 2 - 4 weeks for us to process an application as we ensure that the application is reviewed by our Membership Committee and seen by partners at a monthly teleconference. For more information about the application process, please Contact Us.

Single-funder organizations
Partner	Caveat
ACS	Dollar amounts found in the ICRP database are different than what is reported in the American Cancer Society's Annual Report. The dollar amounts spent on research reported in audited reports include operating expenses of the Research Department. Additionally, the dollar amounts also exclude all grants that were cancelled after being awarded, but include money that was returned from grants cancelled in the current year that were awarded in previous years. The dollar amounts reported in the database are unaudited and include grants awarded each fiscal year, exclusive of grants that cancelled before activation.
CBCRP	The California Breast Cancer Research Program grants are awarded only to individuals or institutions in California. Grants to the University of California receive only direct funds, while grants to other institutions also receive indirect costs (overhead) at 25% or the federally negotiated rate. Collaborative awards are counted in graphs and tables by the number of co-Principal Investigators rather than the number of projects.
Komen	Dollar amounts found in the ICRP database are different than what is reported on Komen\'s website or in Komen\'s Annual Report for the following reasons: Komen commits all funds necessary to support a research grant in the year it is awarded. Therefore, Komen\'s website reports on the full amount of each grant in the year it is initiated, while the ICRP data is annualized, as described. Komen funds research grants to our Scientific Advisors (Scientific Advisory Board members and Komen Scholars) and also provides discretionary funding of research-related projects that are not traditional research grants (e.g. support of the Komen Tissue Bank, ASCO and AACR meeting support). These are included in the overall Research Program spending, as reported in our Annual Report and on our website, but are not included in the ICRP database.
NIH	NIH projects in NIH Reporter assigned to the Spend Category ‘cancer’ are included in the ICRP database from FY2005 onwards. A small number of projects are excluded if essential information is missing (primarily Project title, Institution). Previous years’ data were drawn from the NFRP and may be incomplete. Starting in FY2007 NCI reports funding supplements, etc., for each grant separately instead of including them in the main project, therefore the number of projects may differ significantly from those of previous years. Projects with a cost of $0 include those that were a no-cost extension of the grant or when funding was provided by another NIH institute or center for that FY. NCI dollars in the ICRP database are drawn from NIH reporter and may not match dollars from other NCI-only databases.
Worldwide Cancer Research	Worldwide Cancer Research is unique in that the majority of our funding is awarded to researchers in countries outside the UK. Like many UK research charities, Worldwide Cancer Research only funds the direct costs of research. This creates significant problems in making quantitative comparisons between our funding and that provided by some of the other agencies in the ICRP, which fund both the direct and indirect costs (often called overheads) of research.

UK Organizations that are part of NCRI
Partner	Caveat
NCRI (GENERIC)	NCRI submits data to ICRP on behalf of all UK NCRI members from its Cancer Research Database (CaRD). The database only includes entries where funding can be directly attributed to a set of clearly defined research objectives. This means that the CaRD only contains information on all direct research funding (project, programme, fellowship, unit and institute) financed by NCRI Member organizations, for which an abstract has been submitted and where the project is active in any given financial year (April - March). Examples of funding that are currently outside the scope of CaRD are infrastructure, meeting grants and research management support."
Breakthrough (UK)	The ICRP database includes all Breakthrough Breast Cancer\'s research spend reported through its Annual Reports & Accounts. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some research spend that is already committed may not be included in the ICRP figures. Expenditure on non-research charitable activities and management support costs are excluded from the NCRI, and by extension, the ICRP dataset. For further information on Breakthrough\'s research please visit www.breakthroughresearch.org.uk or email research@breakthrough.org.uk
CR-UK (UK)	The ICRP database includes around 70% of Cancer Research UK\'s direct research spend per financial year as reported through its Annual Reports & Accounts. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on vital research services, technology transfer, meeting grants, research management support and infrastructure to support Cancer Research UK\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Department of Health (UK)	There will always be some variance between the figures available on ICRP and the figures reported publicly by DH. There are two reasons for this. Firstly, there is variance due to different reporting periods (1 April snapshot of ICRP versus full financial year reporting by DH). Secondly, the Department\'s National Institute for Health Research (NIHR) encompasses various expenditure on NHS infrastructure for research relevant to cancer that is not in a format that it is possible to capture for ICRP.
Macmillan (UK)	The ICRP database represents about 90% of Macmillan Cancer Support\'s direct research spend per financial year. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on research management support and infrastructure to support Macmillan Cancer Support\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Scottish Government Health Directorates (UK)	Scottish Government is committed to improve the health of the Scottish population and the Chief Scientist\'s Office (CSO) funds across a broad range of relevant disease areas. Overall, 75% of the CSO spend is committed to research infrastructure in NHS Scotland. This and much other research expenditure is therefore outside the NCRI remit and, by extension, the ICRP dataset.

Canadian organizations who are part of the CCRA
Partner	Caveat
CCRA	Caveats/limitations specific to Canadian Cancer Research Alliance organizations can be accessed here.

Difference	Detail	Impact on investment figures
Not all CCRS participating organizations are included in the ICRP.	For the period 2005–2021, CCRA submitted data to the ICRP for 35 organizations and three now defunct multi-funded initiatives (CBCRA, CPCRI, and CTCRI). Note that the Canadian Breast Cancer Research Foundation merged operations with the Canadian Cancer Society in February 2017 and Prostate Cancer Canada merged in 2020. Importantly, Alberta Innovates did not report any research projects for 2020 and 2021 due to staffing constraints. Projects within the CCRS total 30,218, of which 24,129 were reported to ICRP.	Moderate for years 2020 and 2021
Not all CCRS projects are included in the ICRP.	“Related support” grants (i.e., travel awards, workshops/symposia, LOIs, etc.) are not submitted to ICRP, but are included in reports released by CCRA. In addition, equipment/infrastructure grants through the Canada Foundation for Innovation and for other funders where the cancer relevance weighting is less than 80% are not reported to the ICRP, but are included in CCRA reports. Any project with cancer relevance of less than 20% is also not reported to the ICRP.	Moderate
Co-funded projects are listed by the administering organization.	Projects that are co-funded appear under the administering organization and are not duplicated per funder. Within CCRA reports, however, investments are reported by the actual funders.	Minor
ICRP uses a different approach to calculating annual project investment.	CCRA provides ICRP with the project budget (adjusted for cancer relevance) and start and end dates. A pro-rated calculation is used to derive annual investment. Within the CCRS, prorated calculations on the basis of annual project amounts (where those data are available) are used to calculate the annual investment.	Minor
ICRP uses different site coding conventions.	The cancer site/type codes used within the CCRS are different from ICRP site codes so results by site will vary in some instances.	Minor
ICRP has technical limitations.	ICRP has a technical limit of 12 site codes and 8 CSO codes and this requires truncation for a couple of large-scale projects within the CCRS.	Very minor
CCRA provides less descriptive information about its projects to ICRP.	Lay abstracts are submitted by CCRA to the ICRP in lieu of technical abstracts and in their language of origin. For projects without lay abstracts (and there are a significant number of these), only titles are provided. An English translation is provided alongside all French project titles to facilitate use of the search engine.	No impact on investment figures, but limits full functionality of search engine especially for organizations that do not collect/report lay abstracts.